Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAPITROL vs ACUVAIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciclopirox is a hydroxypyridine antifungal agent that inhibits the uptake of essential elements and amino acids, disrupts fungal cell membrane integrity, and chelates polyvalent cations (e.g., Fe3+, Al3+), inhibiting metal-dependent enzymes such as cytochromes and catalase.
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
Topical treatment of seborrheic dermatitis of the scalp in adults
Reduction of ocular pain and inflammation following cataract surgery,Treatment of ocular itching associated with seasonal allergic conjunctivitis
Apply 1 m L of 1% shampoo twice weekly for 4 weeks, then weekly for maintenance. Use on wet hair, lather for 2-3 minutes, rinse thoroughly.
1 drop in the affected eye 4 times daily.
Terminal elimination half-life is 20-40 hours; clinically, steady-state is achieved within 5-7 days.
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Ciclopirox is primarily metabolized via glucuronidation, with less than 2% excreted unchanged in urine. The major metabolite is ciclopirox glucuronide.
Primarily hepatic via conjugation with glucuronic acid; minor role of cytochrome P450 enzymes. Approximately 50% is excreted as parent drug and metabolites in urine.
Primarily renal (approximately 60-70% as unchanged drug); biliary/fecal elimination accounts for about 20-30%.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
>99% bound to albumin and alpha-1-acid glycoprotein.
>99% bound to plasma proteins, primarily albumin.
0.3 L/kg; indicates distribution primarily into extracellular fluid.
Intravenous administration in animals suggests Vd ~0.15 L/kg, indicating limited distribution; clinically, it distributes into aqueous humor after topical dosing.
Oral: 70-80%; Topical: approximately 5-10%.
Ocular bioavailability is dependent on formulation; systemic bioavailability after topical ocular administration is extremely low (<1%).
No adjustment required as systemic absorption is negligible.
No adjustment required. Drug is minimally systemically absorbed.
No adjustment required as systemic absorption is negligible.
No adjustment required. Drug is minimally systemically absorbed.
Safety and efficacy not established in children under 12 years; use same as adult for ages 12 and above.
Safety and efficacy in pediatric patients have not been established.
No specific dose adjustment; caution with dry or aged skin due to potential irritation.
No specific dosage adjustment is recommended; use same dose as younger adults.
None.
No black box warning for ophthalmic use; however, systemic NSAIDs carry risk of serious cardiovascular and gastrointestinal events. Ophthalmic use rarely associated with corneal adverse events.
Avoid contact with eyes,If irritation or sensitization occurs, discontinue use,Not for oral, ophthalmic, or intravaginal use
Use with caution in patients with bleeding disorders or those on anticoagulants; may prolong bleeding time. Avoid in patients with known hypersensitivities to NSAIDs or aspirin. Can cause corneal keratopathy; discontinue if corneal epithelial breakdown occurs.
Hypersensitivity to ciclopirox or any component of the formulation
Hypersensitivity to any component of the formulation. Active corneal epithelial defect. Patients with aspirin-sensitive asthma.
No known food interactions when applied topically. However, avoid applying immediately before consuming food to minimize accidental ingestion.
No specific food interactions; systemic absorption is minimal with ophthalmic use. Avoid concurrent use of other NSAID eye drops due to additive irritation.
No adequate human studies; animal studies not available. Only minimal systemic absorption occurs with topical scalp application; theoretical risk low. First trimester: unlikely to cause harm due to negligible absorption; however, avoid elective use. Second and third trimesters: no known risks.
Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester. Use during the first and second trimesters should be limited to cases where potential benefit outweighs risk; avoid during the third trimester due to risk of fetal harm.
Minimal systemic absorption; expected to be safe during breastfeeding. M/P ratio not determined. Avoid application to breast area.
Ketorolac is excreted in human milk following systemic administration, but ocular doses produce negligible systemic levels. The M/P ratio is not determined for ophthalmic use. Use with caution in nursing mothers, as the clinical significance is likely low due to minimal systemic absorption.
No dose adjustment required; topical use only.
No dosage adjustment is required for ophthalmic use during pregnancy, as systemic exposure is negligible. However, avoid use in third trimester due to risks. Pharmacokinetic changes in pregnancy do not significantly alter ocular delivery.
Capitrol (chloroxine) is a topical antibacterial shampoo indicated for dandruff and seborrheic dermatitis. It is generally used twice weekly for 2 weeks, then as needed. Avoid contact with eyes and mucous membranes. Discontinue if local irritation or allergic reaction occurs.
Acuvail (ketorolac tromethamine ophthalmic solution 0.45%) is a nonsteroidal anti-inflammatory drug (NSAID) for ocular use. It is preserved with sodium chloride and not benzalkonium chloride, reducing corneal epithelial toxicity. Administer 1 drop twice daily for ocular pain and inflammation following cataract surgery. Use caution in patients with bleeding tendencies or those on anticoagulants due to risk of increased ocular bleeding. Monitor for corneal epithelial defects and keratitis, especially with prolonged use.
Use exactly as directed; do not use more often than prescribed.,Wet hair and scalp thoroughly before applying shampoo.,Massage into scalp and leave on for 2-3 minutes before rinsing.,Avoid contact with eyes; if occurs, rinse thoroughly with water.,Use caution to avoid staining of clothing or jewelry; rinse shampoo off completely.,Consult healthcare provider if condition persists or worsens after 2 weeks.,Inform doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Wash hands before each use; do not touch tip of bottle to eye or any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Contact your doctor if you experience eye pain, redness, vision changes, or if symptoms worsen.,Do not use this medication while wearing contact lenses unless directed by your doctor.,Store at room temperature, keep bottle tightly closed when not in use, and discard within 28 days of opening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CAPITROL vs ACUVAIL, answered by our medical review team.
CAPITROL is a Topical Antimicrobial that works by Ciclopirox is a hydroxypyridine antifungal agent that inhibits the uptake of essential elements and amino acids, disrupts fungal cell membrane integrity, and chelates polyvalent cations (e.g., Fe3+, Al3+), inhibiting metal-dependent enzymes such as cytochromes and catalase.. ACUVAIL is a NSAID Ophthalmic that works by Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAPITROL and ACUVAIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAPITROL is: Apply 1 m L of 1% shampoo twice weekly for 4 weeks, then weekly for maintenance. Use on wet hair, lather for 2-3 minutes, rinse thoroughly.. The standard adult dose of ACUVAIL is: 1 drop in the affected eye 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAPITROL and ACUVAIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAPITROL is classified as Category C. No adequate human studies; animal studies not available. Only minimal systemic absorption occurs with topical scalp application; theoretical risk low. First trimester: unlikely to . ACUVAIL is classified as Category C. Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.